News
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.
The GW VRU contributed critical data needed to approve the use of the Mpox vaccine in adolescents. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children in this wave.
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
The CDC has released a new report on the health and economic benefits of routine childhood immunizations since the creation of the Vaccines for Children (VFC) program in 1994.
It's National Immunization Awareness Month! Getting vaccinated on the recommended schedule is an important part of protecting against many diseases. Please check with your trusted provider to see what vaccines are recommended for you!
The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were…
VRU Director, Dr. David Diemert, attends the annual Joint Coordinating Board meeting of TDR (Special Programme for Research and Training in Tropical Diseases) of the WHO in Geneva, Switzerland